Arrakis Therapeutics, a Massachusetts-based biotechnology company, has raised $75 million in a Series B financing round.
Led by Nextech Invest and venBio Partners, new backers, Omega Funds, HBM Healthcare Investments, GV, WuXi AppTec Venture Fund and Alexandria Venture Investments also participated in the round.
Moreso, existing backers, Canaan Partners, Advent Life Sciences, Pfizer Ventures, Celgene, Osage University Partners among others also joined the funding.
With the new capital raised, Arrakis Therapeutics will develop its pipeline of RNA-targeted small molecules, with the aim of bringing one or more into clinical development.